EXAMINE THIS REPORT ON SEVITERONEL

-mutated tumors. On the other hand, only a fraction of those patients responds to immune checkpoint or PARP inhibitors and in many cases those that do reply often acquire resistance and relapse.Below we clearly show that Even though seviteronel and enzalutamide exhibited constrained result as one agent (IC50 > ten μM), AR knockdown and AR inhibiti